drugset / Trial / NCT00863590
A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
This study assessed the safety, tolerability, and pharmacokinetics of single-dose odanacatib (MK0822) with and without food.
Timeline
- Start
- 2004-06
- Primary completion
- 2005-02
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Odanacatib | Small molecule | 2 mg | Oral |
| Subject | Odanacatib | Small molecule | 5 mg | Oral |
| Subject | Odanacatib | Small molecule | 10 mg | Oral |
| Subject | Odanacatib | Small molecule | 25 mg | Oral |
| Subject | Odanacatib | Small molecule | 50 mg | Oral |
| Subject | Odanacatib | Small molecule | 100 mg | Oral |
| Subject | Odanacatib | Small molecule | 200 mg | Oral |
| Subject | Odanacatib | Small molecule | 300 mg | Oral |
| Subject | Odanacatib | Small molecule | 400 mg | Oral |
| Subject | Odanacatib | Small molecule | 600 mg | Oral |